产品封面图

Visfatin Human

收藏
  • $50 - 2700
  • prospecbio
  • 以色列
  • CYT-318
  • 2025年07月11日
    avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件

      -20°C

    • 保质期

      1年

    • 英文名

      Visfatin Human Recombinant

    • 库存

      大量

    • 供应商

      上海沪震实业有限公司

    • 规格

      5μg/25μg/1mg

    Visfatin Human

    CATALOGUE NUMBER

    CYT-318

    SYNONYMS

    PBEF, Pre-B cell colony-enhancing factor, Nicotinamide phosphoribosyltransferase NAmPRTase, Nampt, MGC117256, DKFZP666B131, 1110035O14Rik.

    INTRODUCTION

    Excess adiposity is the most important risk in the development of insulin resistance and type 2 diabetes mellitus (T2DM). Adipose tissue produces several proteins (adipocytokines) such as leptin, adiponectin, resistin, tumor necrosis factor-?, and IL-6, that modulate insulin sensitivity and appear to play an important role in the pathogenesis of insulin resistance, diabetes, dyslipidemia, inflammation, and atherosclerosis. However, the mechanisms by which fat tissue induces insulin resistance and the role of adipocytokines in the pathogenesis of T2DM have not been well established. Visfatin, also known as pre-B cell colony-enhancing factor (PBEF), is a cytokine that is highly expressed in visceral fat and was originally isolated as a secreted factor that synergizes with IL-7 and stem cell factors to promote the growth of B cell precursors. Visfatin homologs have been identified in carp, invertebrate mollusks, and bacteria, as well as in vertebrates, including humans and the mouse. It has been postulated to play a role in innate immunity.
    Visfatin exerts insulin-mimetic effects that are dose-dependent and quantitatively similar to those of insulin in stimulating muscle and adipocyte glucose transport, and in inhibiting hepatocyte glucose production. Intravenous injection of recombinant visfatin in mice decreased plasma glucose in a dose-dependent fashion. In keeping with its insulin-mimetic effects, visfatin was as effective as insulin in reducing hyperglycemia in insulin-deficient diabetic mice. Visfatin was also found to be bound to and activate insulin receptor, causing receptor phosphorylation and the activation of downstream signaling molecules. However, visfatin and insulin did not compete for binding to the insulin receptor, indicating that the two proteins were recognized by different regions of the receptor. Thus, visfatin might play a role in glucose homeostasis and dysregulation in biosynthesis or signal transduction, and might contribute to the pathogenesis of diabetes.

    DESCRIPTION

    Visfatin Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 466 amino acids. The total molecular mass is 52.6kDa (calculated). The Visfatin is purified by Flag-affinity chromatography.

    SOURCE

    Escherichia Coli.

    PHYSICAL APPEARANCE

    Filtered White lyophilized (freeze-dried) powder.

    FORMULATION

    Visfatin was lyophilized with no additives.

    SOLUBILITY

    Centrifuge vial before opening. When reconstituting the product, gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution. It is recommended to reconstitute the lyophilized product with 20 mM HCl at a concentration of 0.1 mg/mL, which can be further diluted into other aqueous solutions. Wait several minutes for full reconstitution and solubility.

    STABILITY

    Lyophilized Visfatin although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Visfatin should be stored at 4°C between 2-7 days and for future use below -18°C.
    For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
    Please prevent freeze-thaw cycles.

    PURITY

    Greater than 90.0% as determined by SDS-PAGE.

    AMINO ACID SEQUENCE

    MPPNTSKVYS YFECREKKTE NSKLRKVKYE ETVFYGLQYI LNKYLKGKVV TKEKIQEAKD VYKEHFQDDV FNEKGWNYIL EKYDGHLPIE IKAVPEGFVI PRGNVLFTVE NTDPECYWLT NWIETILVQS WYPITVATNS REQKKILAKY LLETSGNLDG LEYKLHDFGY RGVSSQETAG IGASAHLVNF KGTDTVAGLA LIKKYYGTKD PVPGYSVPAA EHSTITAWGK DHEKDAFEHI VTQFSSVPVS VVSDSYDIYN ACEKIWGEDL RHLIVSRSTQ APLIIRPDSG NPLDTVLKVL EILGKKFPVT ENSKGYKLLP PYLRVIQGDG VDINTLQEIV EGMKQKMWSI ENIAFGSGGG LLQKLTRDLL NCSFKCSYVV TNGLGINVFK DPVADPNKRS KKGRLSLHRT PAGNFVTLEE GKGDLEEYGQ DLLHTVFKNG KVTKSYSFDE IRKNAQLNIE LEAAHH.

    BIOLOGICAL ACTIVITY

    The activity is determined by its ability to induce IL-6, IL-1 beta and TNF alpha production from human PBMCs at 100ng/ml.

    USAGE

    ProSpec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • Visfatin定量EIA试剂盒使用说明

        上海西唐生物科技有限公司   021-55229872,  65333639   www.westang.com 人 Visfatin 定量 EIA 试剂盒使用说明   原理 本实验采用双抗体夹心  ELISA 法。用抗人 Visfatin 单抗包被于酶标板上,标准品和样品中的  Visfatin 与单抗结合,加入酶标抗体,形成免疫复合物连接在板上,加入酶底物TMB ,出现蓝色,加终止液硫酸,颜色变黄

    • 大鼠内脂素(Visfatin)ELISA试剂盒 说明书

      上海西唐生物科技有限公司 021-55229872, 65333639 www.westang.com 大鼠内脂素 (Visfatin)ELISA 试剂盒 ( 用于血清、血浆、细胞培养上清液和其它生物体液内 ) 原理 本实验采用双抗体夹心 ABC-ELISA 法。用抗大鼠 Visfatin 单抗包被于酶标板上,标准品和样品中的 Visfatin 与单抗结合,加入生物素化的抗大鼠 Visfatin

    • Human Neuritin说明书

      人 Neuritin 酶联免疫分析(ELISA) 试剂盒使用说明书 本试剂仅供研究使用         目的:本试剂盒用于测定人血清,血浆及相关液体样本 中Neuritin 的含量。 实验原理:    本试剂盒应用双抗体夹心法测定标本中人 Neuritin 水平。用纯化的 Neuritin 抗体 包被微孔板,制成固相抗体,往包被单抗的微孔中加入 Neuritin ,再与 HRP 标记的 Neuritin 抗体结合,形成抗体

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    艾美捷科技有限公司
    2025年07月11日询价
    询价
    深圳欣博盛生物科技有限公司
    2023年10月25日询价
    $50
    上海再康生物科技有限公司
    2025年11月20日询价
    $50
    上海信裕生物科技有限公司
    2025年05月16日询价
    $50
    上海沪震实业有限公司
    2025年07月11日询价
    Visfatin Human
    $50 - 2700